NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing

Source: ET Real Estate
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
- ▸NITI Aayog is actively working on new policies to boost local production of medical and dental devices.
- ▸The government is addressing challenges like complex regulations and cost disadvantages faced by Indian manufacturers.
- ▸This initiative aims to reduce India's dependence on imported medical equipment.
- ▸A stronger domestic manufacturing sector could lead to more affordable healthcare products and job creation.
- ✓NITI Aayog is actively working on new policies to boost local production of medical and dental devices.
- ✓The government is addressing challenges like complex regulations and cost disadvantages faced by Indian manufacturers.
- ✓This initiative aims to reduce India's dependence on imported medical equipment.
- ✓A stronger domestic manufacturing sector could lead to more affordable healthcare products and job creation.
NITI Aayog, the premier public policy think tank of the Government of India, is spearheading efforts to bolster the country's medical and dental device manufacturing industry. The organization is currently exploring a range of policy measures designed to improve local production capabilities, ultimately aiming to reduce India's reliance on imports and foster self-sufficiency in this critical sector.
This strategic push comes amidst a growing recognition of the Indian healthcare sector's needs and the potential for domestic manufacturers to meet them. India, currently, depends significantly on imported medical devices, and strengthening local manufacturing is seen as vital for both economic growth and national health security.
A recent high-level meeting convened by NITI Aayog brought together key stakeholders to discuss the path forward. Participants included a diverse group: domestic manufacturers who are at the forefront of the industry, senior government officials involved in policy formulation, and leading experts from prestigious institutions like IIT Delhi and IIT Mumbai. This collaborative approach underscores the comprehensive nature of the policy exploration.
During these extensive discussions, several key challenges hindering the growth of Indian medical and dental device manufacturers were brought to the forefront. Prominent among these were significant regulatory hurdles, which often add complexity and time to product development and market entry. Additionally, Indian manufacturers frequently face cost disadvantages when competing with established international players, impacting their market share and profitability.
The Association of Indian Medical Device Industry (AiMeD), a leading industry body representing local manufacturers, played a crucial role in these discussions. AiMeD emphatically highlighted the urgent need for simpler and more streamlined regulations to ease the operational burden on local companies. Furthermore, the organization advocated for robust financial support mechanisms tailored to the specific needs of Indian manufacturers, which could help them scale up operations, invest in research and development, and become more competitive globally.
For the average Indian citizen, a boost in domestic medical device manufacturing could translate into several benefits. A stronger local industry could lead to more affordable medical equipment and supplies, potentially reducing healthcare costs in the long run. It could also improve the availability and accessibility of essential devices, especially in remote or underserved areas. Moreover, increased manufacturing activity would undoubtedly create new job opportunities across various skill levels within the country, contributing to economic development.
The ongoing policy exploration by NITI Aayog signifies a determined effort to address systemic issues and create a more conducive environment for 'Make in India' in the medical and dental device segment. The outcomes of these discussions are expected to shape future government policies, paving the way for a robust and self-reliant Indian medical device industry capable of serving both domestic and international markets.
This article is for informational purposes only and does not constitute financial or investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is NITI Aayog doing regarding medical device manufacturing?
NITI Aayog is exploring new policy measures to strengthen India's domestic manufacturing capabilities for medical and dental devices, aiming to foster self-reliance.
Who participated in NITI Aayog's discussions on this topic?
The discussions included domestic manufacturers, senior government officials, and experts from IIT Delhi and IIT Mumbai.
What are the main challenges faced by Indian medical device manufacturers?
Indian manufacturers face significant challenges such as complex regulatory hurdles and cost disadvantages when competing with international players.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate

Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
BreakingHospitals, Clinics May Soon Prominently Display Service Rates
Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.
Related Stories

Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.

Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
BreakingHospitals, Clinics May Soon Prominently Display Service Rates
Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.
BreakingBR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence
NMC Healthcare founder BR Shetty has filed a massive $15 billion (approximately ₹1.25 lakh crore) lawsuit against Bank of Baroda in the Bombay High Court. The suit alleges fraud and negligence, seeking damages for direct losses, consequential harm, and reputational damage.